VAD & Service Provider of Diagnostic Imaging Equipment, Southwest US Radiology Equipment Refurbisher

$13.4M

Revenue

$1.2M

SDE

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a healthcare technology business built around the sale, refurbishment, repair, and maintenance of diagnostic radiology equipment, with a particular specialization in medical diagnostic displays. The company positions itself as one of a small number of global providers able to fully refurbish and service these displays, which is a narrow, technical niche that most generalist medical equipment shops cannot touch. It serves more than 8,000 customers worldwide, spanning major healthcare systems, radiology practices, outpatient imaging centers, physician offices, teleradiology providers, healthcare IT organizations, and even OEM manufacturers.

The financial profile is what makes this interesting: $13.4M in revenue against $1.175M of EBITDA, roughly a 9% margin, with revenue compounding at a stated 27.1% CAGR through the TTM ending July 2026. That growth rate paired with a thin margin tells you this is a business that reinvests into inventory and volume rather than one already optimized for profit extraction. The approved-vendor status with large health systems is a meaningful barrier, since getting onto those vendor lists takes years and reputational trust.

The stated upside levers are proprietary product development (expanding in-house medical display lines, commercializing a foldable diagnostic display platform) and riding the AI workstation and machine learning infrastructure wave in imaging. The seller is a single shareholder evaluating strategic alternatives and open to flexible deal structures, which suggests room to negotiate on price and terms. Operating from a leased 15,000 square foot facility in the Southwest US keeps the asset base light.

Why we like it

Earnings quality rests on a mix of recurring service, repair, and maintenance work layered on top of equipment resale, meaning some revenue renews as hospitals keep imaging displays in service for years. With 8,000+ customers and no obvious concentration flagged, the base is broad, though the thin 9% EBITDA margin means diligence must confirm how much profit is durable versus tied to one-time equipment flips.
The moat is real and rare: management claims to be one of the few global operators able to fully refurbish and service diagnostic medical displays, and the approved-vendor network with major health systems is a genuine barrier that takes years to build. That specialization plus vendor-list status is exactly the kind of boring, technical positioning that keeps competitors out and pricing defensible.
Market tailwinds are strong because diagnostic imaging is a non-discretionary spend for hospitals, and refurbished equipment plus service contracts become MORE attractive when health systems tighten capital budgets in a downturn. Rising AI and machine learning demand in radiology adds a secular growth vector on top of the essential-services floor.
The operator advantage is the 27.1% revenue CAGR combined with an asset-light leased facility, so a buyer inherits momentum without a heavy real estate or fleet burden. A capable operator can push margin by expanding proprietary display lines and reducing reliance on third-party manufacturers, which management already names as the primary lever.

How to improve it

Attack the 9% EBITDA margin directly by shifting mix toward proprietary in-house display products, which management flags as higher margin and less dependent on third-party manufacturers. Even a few points of margin on $13.4M of revenue meaningfully changes the enterprise value.
Convert more of the customer base to recurring service and maintenance contracts rather than transactional repair and resale, locking in predictable revenue from the 8,000+ existing relationships. Contracted uptime and preventive maintenance plans are stickier and command better pricing than break-fix work.
Build out the AI workstation and machine learning infrastructure offering the seller already identifies as demand-driven, using the existing approved-vendor access to cross-sell into health systems that trust the brand. This attaches higher-value hardware and software to an established distribution channel.
Commercialize the foldable diagnostic display platform with a real product roadmap, pricing, and go-to-market plan, since a proprietary hardware differentiator can defend margin and create a moat competitors cannot copy from refurbishment alone. Validate the IP and manufacturing path before assuming this is a near-term revenue driver.
Increase inventory capacity as the seller notes demand is outrunning availability, but do it with disciplined working-capital modeling so you do not tie up cash in slow-moving equipment. Faster fulfillment can capture revenue currently lost to stockouts.
Formalize the approved-vendor relationships into multi-year framework agreements where possible, turning informal vendor-list status into contractual, durable demand. This protects the moat during ownership transition when relationships are most at risk.

Diligence notes

Scrutinize the 27.1% CAGR claim and the TTM ending July 2026, which is a forward-dated period as written, so confirm whether these are actuals, projections, or a blend. Growth math on a two-year window can be distorted by a single large contract or a low base year.
Break revenue into resale versus refurbishment versus recurring service and maintenance, because the durability of the 9% EBITDA depends heavily on how much is repeatable service versus one-time equipment sales. Understand gross margin by line to know where the profit actually lives.
Test customer concentration despite the 8,000-customer headline, since a handful of major health systems or OEM relationships could drive a disproportionate share of revenue and profit. Loss of a top approved-vendor relationship post-sale would be a material risk.
Verify the proprietary display and foldable platform IP: patents, ownership, development stage, and whether the seller counts these as current revenue or speculative upside. Do not pay for optionality that is still on the whiteboard.
Assess key-person and technical-talent risk, because the ability to fully refurbish diagnostic displays is described as rare, meaning a small number of skilled technicians may hold the actual capability. Confirm retention plans and depth of the service bench before closing.
Since no asking price is disclosed and the single shareholder is open to flexible structures, model a range of valuations against the $1.175M EBITDA and stress-test working capital needs given inventory-heavy operations. Negotiate seller financing or an earnout to bridge the growth-claim risk.

Source

Originally listed on BizBuySell. View original listing →